FOR IMMEDIATE RELEASE
ACS News Service Weekly PressPac: November 10, 2021
Reversing new-onset type 1 diabetes with pyramid-like DNA
ACS Applied Materials & Interfaces
Usually diagnosed in children, teens and young adults, type 1 diabetes is an autoimmune disease in which the immune system attacks and destroys insulin-secreting 尾-cells in the pancreas. As a result, people with type 1 diabetes can鈥檛 regulate their blood sugar levels and require insulin treatment for survival. Now, researchers reporting in听ACS Applied Materials & Interfaces听have reversed new-onset type 1 diabetes in mice with pyramid-like DNA molecules called tetrahedral framework nucleic acids (tFNAs).
About 64,000 people in the U.S. are diagnosed with type 1 diabetes each year, according to the Juvenile Diabetes Research Foundation. There is no cure for the disease, and to manage symptoms, people must measure their blood sugar levels throughout the day and administer insulin through an injection or pump. Although scientists still don鈥檛 know exactly what causes the body to turn against itself and attack insulin-secreting cells, people with type 1 diabetes have fewer regulatory T cells (Tregs) 鈥� immune cells that suppress the differentiation and activation of other, self-attacking T cells. In a听听published in ACS鈥櫶�Nano Letters, Yunfeng Lin and colleagues showed that treating mice with tFNAs could prevent type 1 diabetes, in part by increasing Treg numbers. Originally designed to carry other therapeutic molecules into cells, tFNAs have recently been shown to modulate the immune system on their own. Now, the researchers wanted to find out if these molecules could reverse new-onset type 1 diabetes, before pancreatic 尾-cells were completely destroyed.听
The researchers made tFNAs from four single-stranded DNA segments that self-assembled into pyramid-like shapes, called tetrahedrons. But whereas a pyramid is square at its base, tetrahedrons are triangular. Then, every other day for 4 weeks, they injected the tFNAs into 10 mice with new-onset type 1 diabetes, while 10 other diabetic mice were injected with saline. In the control mice, blood glucose levels continued to rise, and 60% of the mice died during the 12-week follow-up period. In contrast, blood glucose levels in mice treated with tFNAs went down to normal levels, and none of the rodents died. In a further analysis of the tFNA-treated mice, the team found that pancreatic 尾-cells were protected, and Tregs were restored to normal levels, while auto-reactive T cells decreased in the pancreas. Although the findings still need to be verified in people, tFNAs are one of the most promising candidates for type 1 diabetes immunotherapy, the researchers say.
The authors acknowledge funding from National Key R&D Program of China and the听.
听
###
The American Chemical 中国365bet中文官网 (ACS) is a nonprofit organization founded in 1876 and chartered by the U.S. Congress. ACS is committed to improving all lives through the transforming power of chemistry. Its mission is to advance scientific knowledge, empower a global community and champion scientific integrity, and its vision is a world built on science. The 中国365bet中文官网 is a global leader in promoting excellence in science education and providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, e-books and weekly news periodical听Chemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a leader in scientific information solutions, its CAS division partners with global innovators to accelerate breakthroughs by curating, connecting and analyzing the world鈥檚 scientific knowledge. ACS鈥� main offices are in Washington, D.C., and Columbus, Ohio.
Registered journalists can subscribe to the to access embargoed and public science press releases. For media inquiries, contact newsroom@acs.org.
Note: ACS does not conduct research but publishes and publicizes peer-reviewed scientific studies.
Media Contact
ACS Newsroom
newsroom@acs.org
###
La sociedad American Chemical 中国365bet中文官网 (ACS) es una organizaci贸n sin fines de lucro fundada en 1876 y aprobada por el Congreso de los Estados Unidos. La ACS se ha comprometido a mejorar la vida de todas las personas mediante la transformaci贸n del poder de la qu铆mica. Su misi贸n es promover el conocimiento cient铆fico, empoderar a la comunidad global y defender la integridad cient铆fica, y su visi贸n es un mundo construido bas谩ndose en la ciencia. La Sociedad es l铆der mundial en la promoci贸n de la excelencia en la educaci贸n cient铆fica y en el acceso a informaci贸n e investigaci贸n relacionadas con la qu铆mica a trav茅s de sus m煤ltiples soluciones de investigaci贸n, publicaciones revisadas por expertos, conferencias cient铆ficas, libros electr贸nicos y noticias semanales peri贸dicas de Chemical & Engineering News. Las revistas de la ACS se encuentran entre las m谩s citadas, las m谩s fiables y las m谩s le铆das en la literatura cient铆fica; sin embargo, la propia ACS no realiza investigaci贸n qu铆mica. Como l铆der en soluciones de informaci贸n cient铆fica, su divisi贸n CAS se asocia con innovadores internacionales para acelerar los avances mediante la preservaci贸n, la conexi贸n y el an谩lisis de los conocimientos cient铆ficos del mundo. Las sedes principales de la ACS se encuentran en Washington, D.C., y Columbus, Ohio.
Los periodistas registrados pueden suscribirse al en EurekAlert! para acceder a comunicados de prensa p煤blicos y retenidos.听 Para consultas de los medios, comun铆quese con newsroom@acs.org.
Nota: ACS no realiza investigaciones, pero publica y divulga estudios cient铆ficos revisados por expertos.鈥�
View larger image
;void(0);){kind=link}